NCT07431827 2026-02-25
KANDLELIT-013
Merck Sharp & Dohme LLC
Phase 3 Not yet recruiting
Clinical Trials
11 trialsNCT07361510 2026-02-19
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Bristol-Myers Squibb
Phase 3 Not yet recruiting
NCT07346053 2026-01-16
Chrono-EVP
British Columbia Cancer Agency
Phase 3 Not yet recruiting
NCT06093425 2025-12-17
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 3 Not yet recruiting
NCT05077215 2025-12-08
Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer
Evergreen Therapeutics, Inc.
Phase 3 Not yet recruiting
NCT07264075 2025-12-04
ILLUMINE
Groupe Oncologie Radiotherapie Tete et Cou
Phase 3 Not yet recruiting
NCT07178730 2025-09-17
ADAPT-TN-IV
West German Study Group
Phase 3 Not yet recruiting
NCT07162883 2025-09-09
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06749925 2025-04-01
Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma
University of Sao Paulo General Hospital
Phase 3 Not yet recruiting
NCT06411171 2024-05-17
Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:
Xijing Hospital of Digestive Diseases
Phase 3 Not yet recruiting
NCT06146777 2023-11-29
Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy
First Affiliated Hospital, Sun Yat-Sen University
Phase 3 Not yet recruiting